
Caribou Biosciences, Inc.: updates and filings
Price
$0.28
November 20, 2026Market cap $31M
What Ploutos Investor adds for Caribou Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 31% since Nov 5, 2026, when the 10-Q these figures come from was filed ($0.41 then, $0.28 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 9, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 6, 2026Restructuring costs, officer or director change, Regulation FD disclosure, other material eventsForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 18, 2026Shareholder voteForm8-K
- Jun 11, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 5, 2026Additional annual meeting materialFormDEFA14A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 1, 2026FilingFormDEFR14A
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 10, 2026Preliminary proxy statementFormPRE 14A
- Mar 31, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 5, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 12, 2025Results of operationsForm8-K
- Nov 3, 2025Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Aug 12, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Aug 12, 2025Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 6, 2026 | 8-K | Restructuring costs, officer or director change, Regulation FD disclosure, other material events | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| Jun 11, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 5, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | DEFR14A | Filing | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 10, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 31, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 5, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 12, 2025 | 8-K | Results of operations | Document |
| Nov 3, 2025 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Aug 12, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Aug 12, 2025 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 23, 2014.
The full analysis
What do Caribou Biosciences's filings show?
The filings are where every one of Caribou Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.